January 3, 2017 (Shareholders Foundation) - An investigation on behalf of investors of Innocoll Holdings PLC (NASDAQ:INNL) shares over potential securities laws violations by Innocoll Holdings and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Innocoll Holdings PLC (NASDAQ:INNL) concerning whether a series of statements by Innocoll Holdings regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Innocoll Holdings PLC reported that its annual Total Revenue declined from $4.50 million in 2014 to $2.59 million in 2015 and that its Net Loss increased from $20.67 million in 2014 to $43.15 million in 2015.

On December 29, 2016, Innocoll Holdings PLC announced that it has received a Refusal to File letter from the United States Food and Drug Administration (FDA) for XARACOLL, the companys product candidate for the treatment of postsurgical pain.

On January 3, 2017, NASDAQ:INNL shares closed at $0.70 per share.